The Role of Peptidyl Arginine Deiminase IV(PADI4) in Cancers.

Abstract

BACKGROUND:

Peptidyl arginine deiminase IV (PADI4, also called PAD4), a Ca2+-dependent posttranslational modification enzyme, catalyzes the conversion of arginine residues to non-coded citrulline residues. Dysregulation of PADI4 is involved in a variety of diseases including rheumatoid arthritis (RA), multiple sclerosis (MS), Alzheimer's disease (AD) and many kinds of malignant tumors.

OBJECTIVE:

The roles of PADI4 in different tumors and the underlying molecular mechanisms are presented in this article.

RESULTS:

PADI4-mediated citrullination is associated with either transcriptional activation or repression in different contexts. Abnormal expression of PADI4 exists in a variety of malignant tumors and affects tumor progression and metastasis. Epithelial-to-mesenchymal transition (EMT), apoptosis, and neutrophil extracellular traps (NETs) may be the underlying molecular mechanisms.

CONCLUSION:

PADI4 plays crucial role in the occurrence, development, and metastasis of tumors, and PADI4 may be an effective biomarker for cancer prognosis and a potential target for cancer treatment.

• Authors: Xiangmei Wu, Yuji Wang, Wenjing Wang
• Journal: Anti-cancer agents in medicinal chemistry (Anticancer Agents Med Chem) Vol. 23 Issue 3 Pg. 256-265 ( 2023) ISSN: 1875-5992 [Electronic] Netherlands
• PMID: 35702765 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• arginine deiminase
• Hydrolases

Topics

• Humans
• Neoplasms (drug therapy)
• Apoptosis
• Epithelial-Mesenchymal Transition
• Hydrolases